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Glucagon-like peptide 1 (GLP-1) is a hormone and a growth factor. GLP-1 mimetics are 
currently on the market as treatments for type 2 diabetes. They also have shown 
neuroprotective properties in animal models of neurodegenerative disorders. In addition, 
the GLP-1 mimetic exendin-4 has shown protective effects in animal models of Parkinson’s 
disease (PD), and a first clinical trial in PD patients showed promising results. 
(Val8)GLP-1-glu-PAL is a new GLP-1 analogue which has a longer biological half-life than 
exendin-4. We previously showed that (Val8)GLP-1-glu-PAL has neuroprotective properties. 
Here we tested the drug in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
mouse model of PD. MPTP was injected (30mg/kg i.p.) along with (Val8)GLP-1-glu-PAL 
(25nmol/kg i.p.) once-daily for 8 days. (Val8)GLP-1-glu-PAL showed good effects in 
preventing the MPTP- induced motor impairment (Rotarod, open field locomotion, swim 
test), reduction in Tyrosine Hydroxylase levels (dopamine synthesis) in the substantia nigra, 
a reduction of activated caspase 3 levels, of TUNEL positive cell numbers, of the 
pro-apoptotic signaling molecule BAX and an increase in the growth signaling molecule 
Bcl-2. The results demonstrate that (Val8)GLP-1-glu-PAL shows promise as a novel 










 1. Introduction 
Parkinson's disease (PD) is one of the common progressive neurological diseases in 
the elderly population. Although the pathogenesis and detailed mechanisms of this 
disease has not been fully elucidated, the main pathological characteristic is the 
progressive loss of dopaminergic neurons, mainly in the substantia nigra pars compacta 
(SNpc). It causes the substantia nigra-striatum pathways to degenerate, and induces a 
decline in the release of the dopaminergic neurotransmitter, and thereby impairs the 
function of motor activity and coordination. It causes many clinical characteristics such as 
resting tremors, bradykinesia, rigidity and postural instability, along with non- motor 
symptoms (Kowal, Dall, Chakrabarti, Storm, & Jain, 2013). Recently, studies have shown a 
link between diabetes and PD. Both diabetes and PD are age-related chronic diseases and 
some pathogenic processes may underlie both conditions (Chen, O'Reilly, Schwarzschild, & 
Ascherio, 2008; Henchcliffe & Beal, 2008; Pradhan, 2007). Insulin de-sensitisation may be 
one mechanism that underlies both conditions. The analysis of clinical data showed that 
an 8–30 % of PD patients were diabetic or glucose intolerant, a significantly higher 
percentage compared to age matched controls (Cereda et al., 2011; Hu, Jousilahti, Bidel, 
Antikainen, & Tuomilehto, 2007; Lu et al., 2014; Miyake et al., 2010; Schernhammer, 
Hansen, Rugbjerg, Wermuth, & Ritz, 2011). In preclinical studies, systemic administration 
of drugs for T2DM, such as insulin (Freiherr et al., 2013), rosiglitazone (Schintu et al., 2009), 
and metformin (Patil, Jain, Ghumatkar, Tambe, & Sathaye, 2014), significantly attenuate 
neuropathology, including the loss of SNpc neurons and the striatal dopaminergic fibers, 
microglial activation, or the expression of pro-inflammatory cytokines, in PD animal 
models. Also, a drug that is on the market to treat type 2 diabetes, Exenatide (exendin-4), 
showed a therapeutic effect in preclinical tests (Harkavyi et al., 2008; Kim, Moon, & Park, 
2009; Li et al., 2009) and in a pilot clinical trial in PD patients (Aviles-Olmos et al., 2013; 
Aviles-Olmos et al., 2014). Exendin-4 is a receptor agonist for the incretin hormone 
Glucagon-like peptide-1 (GLP-1) (Baggio & Drucker, 2007). GLP-1 is a growth factor with 
neuroprotective properties in a range of disease models of chronic neurodegenerative 
disorders (Holscher, 2013). Newer GLP-1 mimetics have been developed, and they have 
longer survival times in the blood stream than exendin-4 (Sadry & Drucker, 2013; Tan & 
Bloom, 2013). We have previously reported good neuroprotective effects of GLP-1 
mimetics in animal models of Alzheimer’s disease (Gengler, McClean, McCurtin, Gault, & 
Holscher, 2012; P. McClean, Parthsarathy, Faivre, & Hölscher, 2011; P. L. McClean & 
Holscher, 2014). However, no data have been published that demonstrate neuroprotective 
effects of these newer and more potent drugs in animal models of PD. We therefore tested 
the effects of a novel protease-resistant GLP-1 analogue, (Val8)GLP-1-glu-PAL, in a mouse 
model of PD. (Val8)GLP-1-glu-PAL has shown good neuroprotective effects in an animal 
model of diabetes (Lennox, Porter, Flatt, & Gault, 2013). We induced PD in mice using the 
chemical MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), which is a precursor of the 
neurotoxin MPP+ that induces classic symptoms of Parkinson's disease by impairing or 
destroying dopaminergic neurons in the substantia nigra pars compacta (SNpc) (Gerlach, 
Riederer, Przuntek, & Youdim, 1991; Nakamura & Vincent, 1986). MPTP is a widely used 
chemical to induce a Parkinson-like state in animals for drug discovery (Kim et al., 2009; 
Kopin & Markey, 1988; Li et al., 2009; Nakamura & Vincent, 1986). Motor activity and key 
biomarkers for PD were evaluated to analyse the neuroprotective efficacy of 
(Val8)GLP-1-glu-PAL. The previously established effective dose of 25nmol/kg ip. was used 





2.1 Experimental Animals 
Adult Male C57BL/6 mice(23±2g) 10±2 weeks old were purchased from the National 
Institute for the Control of Pharmaceutical and Biological Products (NICPBP), were 
maintained in a constant temperature (25±2℃) and humidity (relative 60%-70%) under a 
12h light/dark cycle in animal house, Shanxi Medical University. Animals were allowed free 
access to food and water. All animals procedures were licenced by the ethics committee of 
Shanxi Medical University and performed in accordance to National Institute of Health 
(NIH) guideline (NIH publication NO. 85-23. Revised 1985). During experimental 
procedures, all efforts were made to minimize animal suffering and to reduce the number 
of animal used. 
 
2.2 Chemicals 
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 4% paraformaldehyde (PFA) 
and phosphate buffered saline (PBS) were purchased from Sigma-Aldrich (St Louis, MO, 
USA). Bicinchoninic acid (BCA) protein assay kit was purchased from Beyotime 
Biotechnology Inc. (Zhejiang, China). Sodium chloride, ethylene glycol, and 
3,3-diaminobenzidine (DAB) were purchased from ZSGB-BIO Co. (Beijing, China). All other 
reagents used in the research were obtained from ZSGB-BIO Co. (Beijing, China). 
 
2.3 Antibodies 
Rabbit anti-tyrosine hydroxylase (TH), Bax, Bcl-2, Anti-Pro-caspase3, Goat Anti-rabbit 
IgG H&L (HRP) were obtained from Abcam (Cambridge,UK), Anti-Cleaved-caspase3 was 
purchased from Cell Signaling Technology (Boston, USA). 
 
2.4 (Val8)GLP-1-glu-PAL peptide 
The (Val8)GLP-1-glu-PAL used in this study was purchased from ChinaPeptides Co., Ltd 
(Shanghai, China) to 95% purity. The identity and purity of the peptide was confirmed by 
reversed-phase HPLC and characterised using matrix assisted laser desorption/ionisation 
time of flight (MALDI-TOF) mass spectrometry. The peptide was stored in dry form and 
dissolved in double distilled 0.9%NaCl before experiments. 
 
2.5 Experimental design 
In our experimental design, 56 mice were randomly allocated to four groups (n=14). 
Group1 mice were injected intraperitoneally with saline (0.2ml per mouse) and served as 
control group. Group2 mice received MPTP (30mg/kg wt. ip.)(Zhao et al) once daily for 8 
consecutive days. Group3 mice were injected intraperitoneally with (Val8)GLP-1-glu-PAL 
(25nmol/kg ip.). Group4 was the MPTP+(Val8)GLP-1-glu-PAL group (intraperitoneally MPTP 
injected plus Val8 treated group). (Val8)GLP-1-glu-PAL was dissolved in saline（1mg 
dissolved in 27 ml 0.9%NaCl） was administered after each MPTP injection. After all 
treatment animals were subjected to behavioral, including swimming, rotarod, open-field 
test and perfused afterwards for histological and western blot measurements. 
 
2.6 Behavioral Tests 
Swim test 
In the swim test, each mouse was separately placed in the water tubs (40 cm length
×25cm width×16 cm height), filled up to 12cm with tap water at a temperature of 25±2℃ 
and let swim for 3min as previously described (Haobam, Sindhu, Chandra, & 
Mohanakumar, 2005). The animals were wiped dry immediately after the experiment 
using a dry towel and were returned to cages. Swim score scales were: 0, hind part sinks 
with head floating (swimming time<30s); 1, occasional swimming using hind limbs while 
floating on one side (30s<swimming time< 90s); 2, occasional floating/swimming only 
(90s<swimming time<150s); 3, continuous swimming(swimming time>150s) (Haobam et 
al., 2005; Kavitha, Nataraj, Essa, Memon, & Manivasagam, 2013). The swimming behavior 
of each animal was recorded and analyzed by an observer blind to the experimental 




In the Rotarod test, rotorod apparatus diameter of 3cm, rotational speed of 20rpm, 
the constant temperature of 25±2℃. 
 The rotarod test is a useful method for measuring hypokinesia in a mouse model of 
PD. The rotarod equipment (YLS-4C, Academy of medical sciences in Shandong, China) 
consisted of a rotating spindle and five individual compartments able to simultaneously 
test five mice. Animals were allowed to walk on rotarod before each MPTP injection to 
assess sensorimotor coordination.  
The rotarod test in which animal balances on a rotating drum, is widely used to assess 
motor deficit in neurodegenerative disease models in rodents (Rial et al., 2014). Mice were 
placed on a rod that accelerated smoothly from 5 to 20 rpm over a period of 120s. For 
both protocols, the length of time that each mouse was able to stay on the rod was 
recorded as the latency period to fall, registered automatically by a trip switch under the 
floor of each rotating drum at 5 min rest intervals to prevent stress and fatigue and a 
maximum trial length of 120s pretrial. The experiment was repeated three times for each 
mouse. 
 
Open field test  
 Open field exploratory behavior and spontaneous motor activity were analyzed 
using Open field test (OFT). The environment of detection is quiet and dark. The open field 
is an enclosure, generally square (45cm length×45cm width×45cm height) in shape with 
surrounding walls that prevent escape. Distance moved and standing times are among 
many measures that can be tabulated and reported. Commonly, the field is marked with a 
grid (area 45cm×45cm; size 9cm×9cm) and square crossings. The mice were individually 
placed in one corner of the open field. The crossing numbers (defined as at least three 
paws in a square) were monitored for 5 min by treatment-blinded experimenters seated 
quietly approximately 0.5m distant. The total distance (crossing numbers) and rearing of 
each animal in the field during 5mins of testing session was recorded. After 5min, the 
mouse was removed and the open field was cleaned. The experiment was repeated three 
times for each mouse. 
 
2. 7 Immunohistochemistry 
On the 8th day after the MPTP treatment, mice were deeply anesthetized with 
urethane (ip) and were intracardially perfused saline(20ml), followed by 4% PFA(20ml). 
Brains were immediately removed and post-fixed in 4% PFA overnight (>12h). Brains were 
embedded in paraffin and coronal sections (3μm thick) of the brains were cut on a Leica 
microtome for immunohistochemical study. The sections were pretreated with 3% 
hydrogen peroxide(H2O2) for 10 min at room temperature to remove endogenous 
peroxidase activity. Then, sections were incubated with primary antibodies (rabbit 
anti-mice monoclonal TH, 1:300, Abcam); diluted in PBS in 4°C for overnight. After this, 
sections were incubated with their corresponding secondary antibodies (goat anti-rabbit 
IgG conjugated to horse radish peroxidase, 1:500, Abcam) diluted in PBS for 60min at 37°C. 
In each treatment, the slides were washed at least 3 times with PBS each for 5 min. The 
immunoreactivity was visualized with 3,3'-Diaminobenzidine (DAB) (ZSGB-BIO Co., Beijing 
China) color reaction in SNpc.  
Sections were chosen in accordance with stereological rules: the first section was 
taken at random and every fifth section afterward. Stereology removes bias and possible 
sources of systematic errors (Bondolfi et al., 2002). 
The DAB staining was observed with a ScanScope CS system (APERIO，USA). N=3 
sections per brain were analysed, n=6 per group. 
 
2.8 Western Blotting 
Fresh sections of the midbrain s. nigra area were homogenized (20s homogenization 
and 10s pause×3 times) in an ice cold RIPA buffer (containing 1% Triton X-100, 0.1% SDS, 
1% deoxycholate) and phenyl-methylsulfonyl fluoride (PMSF). The homogenate was 
centrifuged 10,000 rpm for 10 min at 4℃ ,and the supernatant was collect. Protein 
concentration was measured by the method of Bradford (cat.500-0006, Bio-Rad, Hercules, 
CA). Samples were then added with loading buffer to the same concentration, boiled and 
centrifuged. Protein were separated on 10% SDS-polyacrylamide gel and 
electrophoretically transferred to PVDF membrane. The membranes were incubated with 
the blocking buffer containing 5% bovine serum albumin (BSA) for 2h to reduce 
non-specific binding sites and then probed overnight with Rabbit anti-TH (1:500) and 
Rabbit anti-BCl-2 (1:100) and Rabbit anti-Bax (1:200) and Rabbit anti-Pro-caspase3 (1:600) 
(Abcam) and Rabbit anti- Cleaved-caspase3 (1:750)(CST) in 4℃ for overnight, then labeled 
with appropriate secondary antibodies (goat anti-rabbit IgG conjugated to horse radish 
peroxidase, 1:5000, Abcam) was added in room temperature for 2h. To confirm equal 
protein loading, blots were reprobed with aβ-actin antibody (Abcam) at 0.5μg/ml. Protein 
bands were visualized with enhanced chemiluminescence (ECL) (ZSGB-BIO Co., Beijing 
China) and quantified using the image system of Quantity one 4.31 (Bio-Rad, Hercules, CA, 
USA).  
 2.9 Statistical analysis 
All values were presented as the mean ± standard errors (SEM). The statistical 
software SPSS 19.0 was used for statistical analysis. One-way ANOVA tests were used to 
analyse the data with Bonferroni post-hoc tests. A probability value of less than 0.05 was 






3.1 (Val8)GLP-1-glu-PAL improved the MPTP-induced motor impairments 
 
In the swimming test, MPTP impaired motor activity compared to saline controls (p<001). 
An overall one-way ANOVA found a difference between all groups (p<0.0001). In post-hoc 
Bonferroni tests, (Val8)GLP-1-glu-PAL on its own did not affect swimming ability compared 
to saline control. (Val8)GLP-1-glu-PAL prevented or reversed some of the motor 
impairment induced by MPTP. A difference between the MPTP treated groups and the 
(Val8)GLP-1-glu-PAL and MPTP co-administrated group was found (p<001). Data are 
represented as mean ± SEM, n=14 mice in each group. See fig. 1A. 
 
In the rotarod test, (Val8)GLP-1-glu-PAL partially reversed the impairment of staying on the 
rotating rod for 120 seconds that was induced by MPTP (p<0.01). (Val8)GLP-1-glu-PAL on 
its own did not affect performance compared to saline controls. (Val8)GLP-1-glu-PAL 
prevented or reversed some of the motor impairment induced by MPTP. A difference 
between the MPTP treated groups and the (Val8)GLP-1-glu-PAL and MPTP 
co-administrated group was found (p<0.01). Data are represented as mean ± SEM, n=14 
mice in each group. See fig. 1B. 
 
In the Open field assessment (5 min), MPTP reduced the number of rearings (p<0.001) 
compared to controls. (Val8)GLP-1-glu-PAL prevented this effect, and a difference between 
the MPTP treated groups and the (Val8)GLP-1-glu-PAL and MPTP co-administrated group 
was found (p<001). Overall locomotion was severely impaired by MPTP compared to 
controls (p<0.001). The distance traveled was increased in the (Val8)GLP-1-glu-PAL and 
MPTP co-administrated group compared to MPTP along (p<001). See fig. 1C. 
 
 
3.2 Inhibitory Effects of (Val8)GLP-1-glu-PAL on dopaminergic neuronal loss in MPTP 
treated mice 
 
We determined whether (Val8)GLP-1-glu-PAL protects the dopaminergic neurons against 
MPTP toxicity. The expression of tyrosine hydroxylase (TH), a key enzyme for the synthesis 
of dopamine, was analysed. MPTP treatment led to a reduction of TH synthesis and of 
TH-positive neurons in the SN. In the MPTP-only treated mice, the number of TH-positive 
cells in the SNpc was decreased to 35％of the saline control group (p<0.001). However, 
co-administration with (Val8)GLP-1-glu-PAL ameliorated MPTP-induced decrease of 
TH-positive neuron numbers. In comparison with the saline control group, the number of 
TH-positive neurons in Val8+MPTP group was about 60％ (p<0.01). See fig. 2. For western 
blot results see fig. 4. 
 
3.3 (Val8)GLP-1-glu-PAL reduces apoptosis induced by MPTP in the SN 
 
To investigate the preventive effect of (Val8)GLP-1-glu-PAL on the rate of apoptotic DNA 
fragmentation in PD mice brains, the TUNEL assay was performed. Representative TUNEL 
assay results are shown in Fig. 3. The nuclei of the apoptotic cells were stained 
brown/yellow, while those of non-apoptotic cells and the negative control were stained 
blue. Brain sections from the MPTP group showed a significantly higher percentage of cells 
with DNA damage as indicated when compared with brain sections from control group 
(p<0.001). Although the apoptosis index of the MPTP+Val8 group was significantly higher 
compared with that of the control group, (Val8)GLP-1-glu-PAL prevented this effect to 
some degree, and when compared with the MPTP group, the number of positive cells in 
the MPTP+(Val8)GLP-1-glu-PAL group decreased significantly (P<0.01). N=6 per group, data 
shown are means±SEM. See fig. 3. 
 
 
3.4 (Val8)GLP-1-glu-PAL normalised TH expression levels, cell growth signaling and 
reduced apoptotic cell signaling induced by MPTP in the SN 
 
To investigate the effect of (Val8)GLP-1-glu-PAL on key biomarkers, western blot analyses 
were made on SN brain tissue. The level of TH in the SN was decreased by MPTP (p<0.05) 
but partially rescued by (Val8)GLP-1-glu-PAL (p<0.05 compared to MPTP group, fig. 4B). 
Levels of cell growth signaling Bcl-2 molecule were reduced by MPTP (p<0.01) but almost 
normalised by (Val8)GLP-1-glu-PAL p<0.05 compared to MPTP group, fig. 4C). Levels of the 
apoptosis cell signaling molecule BAX were increased by MPTP (p<0.01) and normalised by 
(Val8)GLP-1-glu-PAL (p<0.05 compared to MPTP group, fig. 4D). The levels of the 
procaspase3 protein expression were slightly reduced overall by MPTP (p<0.05) and 
normalised by (Val8)GLP-1-glu-PAL (p<0.05 compared to MPTP group, fig. 4E). Levels of the 
activated cleaved caspase 3 enzyme were much increased by MPTP (p<0.01) and slightly 
reduced by (Val8)GLP-1-glu-PAL (p<0.05 compared to MPTP group, fig. 4F). N=6 per group, 






The results demonstrate that the GLP-1 analogue (Val8)GLP-1-glu-PAL has neuroprotective 
effects in the MPTP mouse model of PD. The motor impairments induced by MPTP were 
clearly visible in the rotarod test of sensorimotor coordination, in the swim test and in the 
open field observation of spontaneous locomotion and exploration. Furthermore, the 
levels of the cell growth second messenger molecule Bcl-2 was reduced, while the 
pro-apoptotic signaling molecule Bax was increased. Activation levels of caspase 3 were 
enhanced by MPTP treatment as well, and the increase in TUNEL positive cells showed 
that apoptosis was much increased. MPTP is a neurotoxin precursor to MPP+, which 
causes symptoms of Parkinson's disease by damaging or destroying dopaminergic neurons 
in the substantia nigra (Gerlach et al., 1991; Nakamura & Vincent, 1986). MPTP is a widely 
used chemical to induce a Parkinson-like state in animals (Kopin & Markey, 1988; 
Nakamura & Vincent, 1986). 
 (Val8)GLP-1-glu-PAL was able to reverse or prevent some of these symptoms. Motor 
activity and somatosensory coordination was improved by the drug, and the biomarkers 
for cell growth and apoptosis were improved. In addition, the expression of the dopamine 
synthetising enzyme TH was much enhanced, suggesting that dopaminergic neurons in the 
SN were functioning again. GLP-1 analogues have shown neuroprotective effects in various 
diseases, such as Alzheimer’s disease, Parkinson’s disease, head trauma or stroke (Darsalia 
et al., 2012; Holscher, 2013; P. L. McClean & Holscher, 2014; Perry & Greig, 2004; Sato et 
al., 2013; Tweedie et al., 2013). Furthermore, two previous studies showed good 
protection of MPTP treated mice using the GLP-1 agonist exendin-4 (Kim et al., 2009; Li et 
al., 2009). Exendin-4 also showed good neuroprotective effects in other animal models of 
PD that use different chemicals to induce PD like symptoms, 6-OHDA or LPS injection into 
the brain (Bertilsson et al., 2008; Harkavyi et al., 2008). More importantly, a pilot clinical 
trial in PD patients showed first positive effects (Aviles-Olmos et al., 2013; Aviles-Olmos et 
al., 2014), and a phase II trial is currently ongoing. Exendin-4 was the first GLP-1 receptor 
agonist to be marketed as a drug treatment for type II diabetes (Baggio & Drucker, 2007). It 
has a short half-life of around 4 hours in the blood stream and needs to be injected 
twice-daily. Therefore, newer GLP-1 analogues have been developed with a much 
enhanced half-life (Campbell & Drucker, 2013; Holscher, 2010) One of these is liraglutide, 
which is GLP-1gluPAL, human GLP-1 that has been acetylated to enhance the half-life in 
the blood stream. It does not have the amino acid substitution at position 8 that 
Val(8)GLP-1(glu-PAL) has. This substitution prevents cleavage by the DPP-IV protease 
(Green, Gault, O'Harte, & Flatt, 2005) and enhances the biological half life in the blood 
stream. We have shown in a previous study that Val(8)GLP-1(glu-PAL) is neuroprotective 
and protects memory and synaptic plasticity in diabetic animals (Lennox et al., 2013). We 
also have previously shown that liragutide and the newer diabetes drug lixisenatide are 
protective in the MPTP mouse model of PD (Liu et al., 2015). Here, we demonstrate for the 
first time that Val(8)GLP-1(glu-PAL) is also neuroprotective in this mouse model of PD. 
However, Val(8)GLP-1(glu-PAL) will have to be tested in other animal models of PD that use 
different chemicals to induce PD- like symptoms such as 6-OHDA or LPS injection into the 
brain (Bertilsson et al., 2008; Harkavyi et al., 2008), and in transgenic mouse models that 
express human mutated genes that are known to induce Parkinson’s disease (Bobela, 
Zheng, & Schneider, 2014; Giraldez-Perez, Antolin-Vallespin, Munoz, & Sanchez-Capelo, 
2014). Another important test to be conducted is to treat animals after inducing the PD 
lesion in order to assess the regenerative effect of the novel drugs. As GLP-1 mimetics are 
already on the market as treatments for type II diabetes and are well received, it would be 
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Fig. 1: (Val8)GLP-1-glu-PAL improved the MPTP-induced motor impairments 
1A: In the swimming test, MPTP impaired motor activity compared to saline controls 
(two-way ANOVA, p<001). (Val8)GLP-1-glu-PAL prevented some of the motor impairment 
induced by MPTP. A difference between the MPTP treated groups and the 
(Val8)GLP-1-glu-PAL and MPTP co-administrated group was found (p<001).  
1B: In the rotarod test, (Val8)GLP-1-glu-PAL partially reversed the impairment of staying on 
the rotating rod for 120 seconds that was induced by MPTP (p<0.001). A difference 
between the MPTP treated groups and the (Val8)GLP-1-glu-PAL and MPTP 
co-administrated group was found (p<001). 
1C: In the Open field assessment (5 min), MPTP reduced the number of rearings (p<0.001) 
compared to controls. A difference between the MPTP treated groups and the 
(Val8)GLP-1-glu-PAL and MPTP co-administrated group was found (p<001). Overall 
locomotion was severely impaired by MPTP compared to controls (p<0.001). The distance 
traveled was increased in the (Val8)GLP-1-glu-PAL and MPTP co-administrated group 
compared to MPTP along (p<001).  
Post-hoc analysis of day-to-day differences are shown between the MPTP group and the 
MPTP+(Val8)GLP-1-glu-PAL group to indicate the protective effect of the drug. *=p<0.05; 
**=p<0.01; ***=p<0.001. Data are represented as mean ± SEM, n=14 mice in each group. 
 
Fig 2: Protective effects of (Val8)GLP-1-glu-PAL on dopaminergic neurons in the SN. The 
expression of tyrosine hydroxylase (TH), a key enzyme for the synthesis of dopamine, was 
reduced by MPTP in the SN to 35％of the saline control group (p<0.001). 
(Val8)GLP-1-glu-PAL ameliorated MPTP-induced decrease of TH-positive neuron numbers. 
In comparison with the saline control group, the number of TH-positive neurons in 
Val8+MPTP group was increased (p<0.01). Length of image = 1mm. 
 
Fig. 3: TUNEL assay in the SN. The number of TUNEL positive cells was much increased in 
the MPTP group. (Val8)GLP-1-glu-PAL prevented this effect to some degree. Data shown as 
means±SEM, n=3 per group. Sample images are shown, A=control; B=MPTP; 
C=(Val8)GLP-1-glu-PAL; D=MPTP+(Val8)GLP-1-glu-PAL. Calibration bar = 100µm. **= P<0.01, 
***=P<0.001.  
 
Fig. 4: To investigate the effect of (Val8)GLP-1-glu-PAL on key biomarkers, western blot 
analyses were made on SN brain tissue. 4A: sample gel lanes with ß-actin loading control. 
4B: The level of TH in the SN was decreased by MPTP but partially rescued by 
(Val8)GLP-1-glu-PAL. 4C: Levels of cell growth signaling Bcl-2 molecule were reduced by 
MPTP but almost normalised by (Val8)GLP-1-glu-PAL. 4D: Levels of the BAX apoptosis cell 
signaling molecule were increased by MPTP and normalised by (Val8)GLP-1-glu-PAL. 4E: 
levels of the pro-caspase3 protein expression were slightly reduced overall by MPTP and 
normalised by (Val8)GLP-1-glu-PAL. 4F: Levels of the activated cleaved caspase 3 enzyme 
were much increased by MPTP and slightly reduced by (Val8)GLP-1-glu-PAL. N=3 per group, 
data shown are means±SEM. *=p<0.05, **=p<0.01 compared to control, #=p<0.05 
compared to MPTP group. 
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